-
Company Insights
Innovation and Patenting activity of Lowe~s Companies Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Lowe~s Companies Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
NewM-PESA – Competitor Profile
M-PESA is a mobile-based fund transfer and micro-level banking service available to customers of Safaricom, Kenya’s largest mobile network. Introduced in 2007, the service has become a primary channel for fund transfers in the country. Originally developed as a low-cost microfinance loan repayment system, it was extended as an open platform to remit funds and make consumer payments due to its rising popularity. This was largely a result of factors such as the high cost of remitting funds through banks,...
-
Sector Analysis
NewHydrogen Transition Market Outlook and Trends, Deals, Contracts, Policies, Projects and Key Players, Q2 2024
The global total active and pipeline capacity of low-carbon hydrogen currently stands at over 204mpta, with 15 new hydrogen projects announced in Q1 2024 adding over 350ktpa of capacity. To date, the total active and pipeline capacity of low carbon hydrogen reaches just under 204mtpa, of which 92% and 8% comes from green and blue plants, respectively, and just 0.08% from purple and turquoise combined. Over 171 mtpa comes from feasibility stage projects (those that are announced or in feasibility...
-
Product Insights
NewLikelihood of Approval Analysis for Prader-Willi Syndrome (PWS)
Overview How likely is it that the drugs in Prader-Willi Syndrome (PWS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prader-Willi Syndrome (PWS) Overview Prader-Willi syndrome (PWS) is a rare congenital...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Low-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Low-Grade Glioma Drug Details: Afatinib dimaleate (Giotrif, Gilotrif,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Refractory Multiple Myeloma Drug Details: Afatinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Esophageal Cancer Drug Details: Afatinib dimaleate (Giotrif, Gilotrif,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Lymphoma Drug Details: Afatinib dimaleate (Giotrif, Gilotrif, Xovoltib)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Cutaneous Squamous Cell Carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plixorafenib in Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plixorafenib in Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plixorafenib in Glioma Drug Details: FORE-8394 (PLX-8394) is under development for the treatment...